Roche to acquire 89bio, and its phase 3 FGF21 analog for the therapy of moderate to severe MASH for US $3.5 billion
On Sept. 17, 2025, Roche announced that it has entered into a definitive merger agreement to acquire 89bio,…
Biotechnology | Disease | FDA | Therapeutics
Corstasis Therapeutics Announces FDA Approval of ENBUMYST™ (bumetanide nasal spray) for the Treatment of Edema Associated with Congestive Heart Failure, Liver Disease and Kidney Disease
On Sept. 15, 2025, Corstasis Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved ENBUMYST™…
UK trial launches to transform Alzheimer’s diagnosis with simple blood test
On Sept. 10, 2025, a major University of London (UCL)-led clinical trial, aiming to transform the diagnosis of…
Novartis to acquire Tourmaline Bio and pipeline for atherosclerotic cardiovascular disease, valued at $1.4 Billion
On Sept. 9, 2025, Novartis announced that it has entered into an agreement to acquire Tourmaline Bio, a…
Nearly half of people with diabetes don’t realize they have the disease
On Sept. 8, 2025, the Institute for Health Metrics and Evaluation (IHME) at the University of Washington School…
Hope for diabetes: CRISPR-edited cells pump out insulin in a person — and evade immune detection
On Sept. 5, 2025, in a medical first, researchers report that they have implanted CRISPR-edited pancreas cells into…
Golden Goose Award Honors Federally Funded Breakthroughs in Cancer Treatments and Disease Diagnostics
On Sept. 3, 2025, The Golden Goose Award, which spotlights obscure, silly sounding or odd fundamental discovery research that…
C2N Diagnostics Expands St. Louis Headquarters to Meet Global Need for Answers to Alzheimer’s Disease
On Sept. 3, 2025, C2N Diagnostics (C2N), a specialty diagnostics company announce that its early achievements while based…
Amgen to Invest $600 Million in New State-of-the-Art Center for Science Innovation at U.S. Headquarters
On Sept. 2, 2025, Amgen announced plans to invest more than $600 million in a new, state-of-the-art center…
OMass Therapeutics announces Collaboration and License Agreement for IBD with Genentech Worth $420 Million
On Sept. 2, 2025, OMass Therapeutics announces an exclusive collaboration and license agreement with Genentech, a member of…
Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement
On Sept. 2, 2025, Arrowhead Pharmaceuticals announced a global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead’s…
Biotechnology | Diagnostics | Disease | Neurology | Oncology
New genetic biomarker flags aggressive brain tumors
On Sept. 1, 2025, a multi-institutional study suggests that typically classifiication of meningiomas by appearances may be deceiving…
new resource, MacroMap, provides a rich dataset that researchers can use to explore genetic mechanisms behind complex diseases
On Aug. 27, 2025, scientists from the Wellcome Sanger Institute reveal insights into how our genes influence the…
AbbVie to Acquire Gilgamesh Pharma’s Investigational Therapy for Major Depressive Disorder for $1.2 Billion
On Aug. 25, 2025, AbbVie and Gilgamesh Pharmaceuticals announced a definitive agreement under which AbbVie will acquire Gilgamesh’s…
In a first, pig lung survives and functions—briefly—in a person
On Aug. 25, 2025, in a small step forward for the long-struggling field of xenotransplantation, surgeons in China…
C2N Diagnostics Expands the PrecivityAD2™ Alzheimer’s Disease Blood Test Intended Use to Patients 50 Years and Older
On Aug. 25, 2025, C2N Diagnostics (C2N) announced lower age limit addresses increasing calls from clinicians seeking access…
Mayo Clinic research set to launch aboard NASA mission to International Space Station to explore new therapies for bone loss
On Aug. 22, 2025, the Mayo Clinic announced that its pioneering exploration of stem cell-based therapies for bone…
MSDH Declares Public Health Emergency on Infant Mortality
On Aug. 21, 2025, the Mississippi State Department of Health (MSDH) declared a public health emergency in response…
Eliminating tobacco use could reduce age-related macular degeneration
On Aug. 21, 2025, the Institute for Health Metrics and Evaluation (IHME) announced a recent study aimed to…
New Method Advances Reliability of Ai with Applications in Medical Diagnostics
On Aug. 20, 2025, two studies led by Johns Hopkins Kimmel Cancer Center, Ludwig Center, and Johns Hopkins Whiting School of…
Biggest shake-up in type 2 diabetes care in a decade announced
On Aug. 20, 2025, the National Institute for Health and Care Excellence (NICE) announced that millions of people…
Biotechnology | Disease | FDA | Medicine | Therapeutics
Novo Nordisk lowers cost of Ozempic® to $499 per month for self-paying patients
On Aug. 18, 2025, Novo Nordisk announced the launch of a new offer that enables self-paying, eligible, type…
Biotechnology | Disease | FDA | Therapeutics
Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
On Aug. 15, 2025, Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved a…
Precigen Announces FDA Approval of PAPZIMEOS, the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis
On Aug. 15, 2025, Precigen announced that the US Food and Drug Administration (FDA) has approved PAPZIMEOS™ (zopapogene imadenovec-drba)…
Using generative AI, researchers design compounds that can kill drug-resistant bacteria
On Aug. 14, 2025, with help from artificial intelligence, researchers from Massachusetts Institute of Technology (MIT) announced they…
Bayer and Kumquat Biosciences enter global $1.3 Billion license and collaboration in precision oncology
On Aug. 12, 2025, Bayer and Kumquat Biosciences, a clinical-stage biotech company founded by pioneers of the KRAS…
CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation
On Aug. 6, 2025, CareDx announced the publication of the Kidney Allograft Outcomes AlloSure Registry (KOAR) study in…
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma
On Aug. 6, 2025, Jazz Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Modeyso™ (dordaviprone)…
Biotechnology | Diagnostics | Disease | Non-Profit Research | Therapeutics | Vaccine | Women's Health
Gates Foundation Announces Catalytic Funding to Spark New Era of Women-Centered Research and Innovation
On Aug. 4, 2025, The Gates Foundation announced a $2.5 billion commitment through 2030 to accelerate research and…
UK Biobank celebrates completion of world’s largest human imaging study with landmark events
On Aug. 4, 2025, UK Biobank announced it had reached a historic milestone – completing 100,000 whole-body imaging…